BUSINESSFINANCIAL TIMES WORLD
Patent cliffs aren’t the only driver of the biotech M&A boom
The biotech M&A boom is being driven by factors beyond patent cliffs, with many deals this year targeting early-stage assets.
Related Signal
Adjacent reporting
- China's biotech boom alarms Western lawmakers, investors
- China’s biotech industry sees global expansion as unstoppable, despite US pressure
- China’s biotech industry sees global expansion as unstoppable, despite US pressure
- Cross-border biotech deals grow more complex as US targets China investment links
- Cross-border biotech deals grow more complex as US targets China investment links